Recently, the FDA proposed guidance that would update the accelerated approval pathway for cancer drugs. Although the guidance includes important provisions, it could be strengthened.
No takes yet. Share an insight, caveat, or question.
Gyawali et al. (2023) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: